Abiopharma

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Novo Nordisk International Operations Commits to Veeva Vault CRM

New Form 15-12G - Clearside Biomedical, Inc. Filed: 2026-01-07 AccNo: 0001193125-26-005412 Size: 11 KB

KAMADA (KMDA) Files Form 6-K

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

Gain Therapeutics Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

Avient To Hold Fourth Quarter 2025 Conference Call

Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones